Navigation Links
Dyadic Netherlands To Develop Enzymes For EU-Funded Research Consortium
Date:7/2/2012

JUPITER, Fla. and WAGENINGEN, The Netherlands, July 2, 2012 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that its research and development center in the Netherlands is a member of the Bio-Mimetic Project, a new multidisciplinary research consortium that has been awarded a EUR 3.5 million grant from the European Community's Seventh Framework Programme (FP7) of the European Community for Research, Technological Development and Demonstration Activities. The European consortium is commencing a three year research project entitled, "New Bio-Inspired Processes and Products from Renewable Feedstock" which will employ environmentally-friendly technologies to convert the renewable agricultural waste stream, lignin, into high value sustainable commercial products such as adhesives, detergents and cosmetics.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

Wim van der Wilden, the General Manager of Dyadic Netherlands, stated, "We are very pleased to have the opportunity to work with such fine organizations on a highly innovative project where we can demonstrate the efficacy and productivity of our C1 technology to use green chemistry to find commercial applications for lignin. If successful, this project will be a promising step forward in using this renewable waste stream to replace traditional toxic, expensive and high energy consuming processes."

As part of the Bio-Mimetic Project, Dyadic Netherlands will receive approximately EUR 400,000 to develop enzymes using Dyadic's patented and proprietary C1 platform technology to degrade and modify lignin so that it can be used to create these high value commercial products.

Procter & Gamble Technical Centres Limited (P&G UK) will serve as the coordinator of the Bio-Mimetic Project Consortium which, in addition to Dyadic Netherlands, consists of the following participants:

  • Fraunhofer Institute IFAM (Germany)
  • The University of Rome Tor Vergata (Italy)
  • MAVI Sud s.r.l. (Italy)
  • Gulgi B.V. (The Netherlands)
  • Compagnie Industrielle de la Matiere Vegetale (CIMV)(France)
  • Procter & Gamble Eurocor N.V. (P&G Brussels Innovation Centre)(Belgium)
  • CiaoTech s.r.l (Italy)
  • The University of Manchester (United Kingdom)

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, industrial enzyme and biopharmaceutical industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.

Dyadic Netherlands is a wholly owned subsidiary of Dyadic based in Wageningen, The Netherlands that conducts research and development activities for the benefit of Dyadic, its collaborators and customers. Please visit Dyadic Netherlands' website at www.dyadic.nl.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research
2. World Renowned Inventor, Donald Spector, Develops Patent For Wireless Electric Acupuncture Patches
3. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
4. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
5. Berg Pharma and the Parkinsons Institute ink R&D collaboration to drive disease understanding and accelerate therapeutic and diagnostic development in Parkinsons Disease
6. Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics
7. Developers: Deadline Approaching for Allscripts Million Hearts CDS Challenge
8. AIUM and AUA Guideline Development Leads To Practice Accreditation For Urologic Ultrasound
9. Omnyx Share Their Insight on Agile Software Development for Medical Devices
10. Softway Solutions Develops Award-Winning Health App for Texas Heart Institute
11. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 The ... world , s first dual therapy stent, ...   OrbusNeich, a global company specializing in ... portfolio to include products to treat peripheral artery disease. ... first entry devices for lower limb and arteriovenous (AV) ...
(Date:5/24/2016)... 2016 Dutch surgeons have launched a ground-breaking ... world and treat patients on a global scale. Medical professionals from ... Asia and the US have already signed up ... networking in a totally secure environment. Education  ... working together with a surgeon at Harvard to treat a bomb ...
(Date:5/23/2016)... Mich. , May 23, 2016 Diplomat Pharmacy, ... third annual Fellowship and Internship programs. The hands-on learning ... The full-time, paid Fellowship and ... Flint, Michigan . Fellows and interns are provided ... Flint at the Riverfront Residence ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... 25, 2016 , ... Consumer access to organic foods and grower access to ... of whole grain cereals and other plant-based foods, will introduce the first consumer product ... wheat processed by Hesco/Dakota Organic Products. , The transitional designation means the cereal was ...
(Date:5/25/2016)... ... 2016 , ... American Spine in Frederick, Maryland is pleased ... in the Montgomery County, Howard County and Washington, D.C. areas, renowned spine specialist, ... Spine every Monday. He will also perform surgeries in our Germantown surgical center ...
(Date:5/24/2016)... ... 24, 2016 , ... PhishLine, the best-in-class, enterprise level security ... Vice President of Sales. Cifolelli’s primary responsibilities include management of the company’s ... expanding field of organizational social engineering. , “We are delighted to have ...
(Date:5/24/2016)... ... May 24, 2016 , ... i2i, a national ... website at its “Transforming Outcomes” User Conference in Las Vegas on May 19-20, ... success to set the market standard for meaningful population health management. The ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, and therefore life ... advantaged communities providing richer opportunities. Recognizing the key role of housing in this ... (b) school choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) ...
Breaking Medicine News(10 mins):